BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
about
Role of Biomarkers in the Development of PARP InhibitorsHomozygous mutation of MTPAP causes cellular radiosensitivity and persistent DNA double-strand breaks.BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerThe sesquiterpene lactone dehydroleucodine triggers senescence and apoptosis in association with accumulation of DNA damage markers.C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsInferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells.Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence.Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatmentThe role of PARP1 in the DNA damage response and its application in tumor therapy.Reversion of the ErbB malignant phenotype and the DNA damage response.Resistance to PARP-Inhibitors in Cancer Therapy.DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy.Tudor: a versatile family of histone methylation 'readers'.Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer.Epistasis in genomic and survival data of cancer patients.A landscape of synthetic viable interactions in cancer.Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.Mechanisms of suppression: The wiring of genetic resilience.BRCA1 recruitment to damaged DNA sites is dependent on CDK9.Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responsesMechanisms of oncogene-induced genomic instability.Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51.The Genome-Wide Interaction Network of Nutrient Stress Genes in Escherichia coli.Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsAurora kinase B dependent phosphorylation of 53BP1 is required for resolving merotelic kinetochore-microtubule attachment errors during mitosis.Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytesRoles of BCCIP deficiency in mammary tumorigenesis.Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination.Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.PARP inhibitors: the journey from research hypothesis to clinical approval.A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.
P2860
Q26753159-7B71F1B9-0415-4DAD-A4B7-4C14D6E2798EQ30413950-7AB3CE10-E10E-489A-A95E-6C064878F9BDQ34493362-69034C38-559C-46E1-9D7B-6B143293D64BQ34558399-C9A3A1B3-957A-46E9-861B-991E0A9F5BE6Q34769289-95A7910C-4382-4DB4-8E98-A7482BBF4DDBQ35837949-4E1C1E1B-FA65-4365-A7B5-904702103D8CQ36038823-FB0907FA-B013-42DE-BC5D-6381380BF5E8Q36111892-9CCD2C0B-DCC7-4C4A-9685-619D685AE30DQ36490203-DEA75CB7-F5E0-41B9-AA86-4F173F9D40C0Q36548227-17A910F4-820D-4A3B-9912-8BDE8248EF59Q37309834-D7235DD5-3407-4F92-9C70-A51D2D42AD57Q37669695-DF4046C3-2CFD-4AAB-A66C-B2909A9B00DDQ38015737-FB033176-FB7D-4D09-B167-8AA7F9579B4DQ38047648-7B6E2ABF-D180-4022-9F09-B8DC2D763359Q38085600-C73BC14D-BE49-4B0B-92E3-FB19BC9156D7Q38106985-65E93564-2C1D-4261-A774-156B759D1CA2Q38137526-DB921483-4DE8-41FB-9B3F-83A0B1610B5BQ38258602-0974DB9E-66E9-49C4-B290-B411BFB63485Q38692827-882AEFB8-12C2-4986-A0D9-E99A9CAB1808Q38720911-A96F060D-A4ED-4BBD-A2F2-8C1AA2E63C26Q38722189-1D79F71A-1C70-45BC-84D0-7FFF70C9636CQ38743147-25371D89-8C3C-47EB-944A-270C3D48A37DQ38917645-505FD1A3-0273-4703-8B09-AC8B88BE7252Q38981181-6D78C88C-061F-4A83-A094-661FB3736E7FQ39078422-AD6B995C-1499-4BAD-9C18-6D760509F6D4Q39082252-7DC6089D-3B9E-4C07-9322-82C610888E4CQ39159676-B5A2C6C3-3CBE-408E-9E96-456729037499Q39455545-B3E6F2DB-CB58-423A-AA2C-3C5E116B4234Q41472052-67A26AC2-BAE9-47B7-A36D-BA9A92DE6199Q41529398-99011E7F-7C57-4B84-B604-40E3E5BC80CEQ42672281-3CCC57C3-0AF9-415E-923D-BED8295AC106Q50540192-DD58D37F-C950-4A5E-B7E4-3E5CD3756638Q52721696-69C0DE28-233C-4415-AFCD-C53DE503122FQ53682668-220677E8-0A32-4429-88BA-8E7BD2807933Q54487776-39836F47-6031-443D-8603-DB5EB3076078
P2860
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@ast
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@en
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@nl
type
label
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@ast
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@en
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@nl
prefLabel
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@ast
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@en
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@nl
P2860
P356
P1476
BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
@en
P2093
Shridar Ganesan
P2860
P356
10.1093/JMCB/MJQ055
P577
2011-02-01T00:00:00Z